[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434929":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":42,"centralContacts":47,"locations":56,"responsibleParty":72,"collaborators":75,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":10,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Queen Mary University of London","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"HCV Negative",null,"At initial screen, this population will be HCV negative via the diagnostic testing. They will be eligible if they fulfil the following:\n\n1. over 18 yrs old.\n2. willing to participate\n3. no previous history of therapy with oral medication for chronic HCV infection",[13],"Diagnostic Test: HCV Antibody test (Point of care)",{"label":15,"type":10,"description":16,"interventionNames":17},"HCV Positive with first-line treatment success","At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12\u002F24 week treatment of sofosbuvir plus daclatasvir. After treatment, their blood sample will show that they have achieved a sustained virological response (SVR) defined as HCV RNA undetectable.",[18],"Diagnostic Test: HCV RNA (PCR)",{"label":20,"type":10,"description":21,"interventionNames":22},"HCV positive with first-line treatment failure","At the initial screen, this population (approx. 5000) will be HCV RNA positive and will undergo 12\u002F24 week treatment of sofosbuvir\u002Fdaclatasvir. After treatment, this proportion of people will NOT achieve an (SVR - defined as HCV RNA undetectable).",[18],{"label":24,"type":10,"description":25,"interventionNames":26},"Cirrhotic Patients","Hepatitis C RNA positive that have cirrhosis",[27],"Diagnostic Test: AST\u002FALT and platelets measurement",[29,34,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DIAGNOSTIC_TEST","HCV RNA (PCR)","We will test HCV positive patients after treatment to observe if they achieve SVR",[15,20],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"HCV Antibody test (Point of care)","HCV antibody test used to establish if patients have had or are actively infected with HCV",[9],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"AST\u002FALT and platelets measurement","AST\u002FALT and platelets to determine APRI score",[24],[43],{"name":44,"affiliation":45,"role":46},"Graham R Foster, MBBS","Queen Mary University","PRINCIPAL_INVESTIGATOR",[48,52],{"name":44,"role":49,"phone":50,"phoneExt":10,"email":51},"CONTACT","07968836267","g.r.foster@qmul.ac.uk",{"name":53,"role":49,"phone":54,"phoneExt":10,"email":55},"Naheed Choudhry, Phd","07951160549","naheedchoudhry1@gmail.com",[57],{"facility":58,"status":59,"city":60,"state":10,"zip":10,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Aga Khan University","RECRUITING","Karachi","Pakistan","PK",{"type":64,"coordinates":65},"Point",[66,67],67.0104,24.8608,{"lat":67,"lon":66},[70],{"name":71,"role":49,"phone":10,"phoneExt":10,"email":10},"Saeed Hamid, MBBS",{"type":46,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Naheed Choudhry","Senior Project Manager",[76,77,79,81],{"name":58,"class":6},{"name":78,"class":6},"Dow University of Health Sciences",{"name":80,"class":6},"University of Oxford",{"name":82,"class":6},"University of Bristol","100434929","treating-hepatitis-c-in-pakistan-strategies-to-avoid-resistance-to-antiviral-drugs-100434929",false,"NCT04943588","Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","Inclusion Criteria:\n\n* Adults over 18yrs old\n* Willing to undergo hepatitis C testing\n* Able and willing to give informed consent\n* Willing to return in 12 months time for repeat testing\n* Resident in area and not planning to leave the region\n\nExclusion Criteria:\n\n* Unwilling to give consent\n* Unwilling or unable to undergo the necessary procedures\n* Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.\n* Co-morbidities limiting life expectancy to less than 12 months",true,"ALL","18 Years","100 Years",{"count":94,"type":95},25000,"ESTIMATED","1 Year","OBSERVATIONAL","We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.",[100],"Hepatitis C, Chronic","2025-03-21",{"date":103,"type":104},"2025-03-24","ACTUAL",{"date":106,"type":104},"2021-11-01",{"date":108,"type":95},"2026-01-30",{"name":5,"class":6},1]